Namibia - English - Namibia Medicines Regulatory Council

bayer (pty) ltd - gadopentetate dimeglumine - injection - each 1 ml solution contains 469,01 mg gadopentetate dimeglumine

Namibia - English - Namibia Medicines Regulatory Council

bayer (pty) ltd - gadopentetate dimeglumine - injection - each 1 ml solution contains 469,01 mg gadopentetate dimeglumine

Namibia - English - Namibia Medicines Regulatory Council

bayer (pty) ltd - gadopentetate dimeglumine - injection - each 1 ml solution contains 469,01 mg gadopentetate dimeglumine

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

dimeglumine gadopentetate 469mg

New Zealand - English - Medsafe (Medicines Safety Authority)

regional health ltd - gadobenate dimeglumine 0.529 g/ml equivalent to to 0.5 m gadobenic acid - solution for injection - 0.529 g/ml - active: gadobenate dimeglumine 0.529 g/ml equivalent to to 0.5 m gadobenic acid excipient: water for injection - multihance is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (mri) of the liver and central nervous system (cns). multihance is indicated, for the detection of focal liver lesions in patients with known or suspected primary liver cancer (eg. hepatocellular carcinoma) or metastatic disease. multihance is also indicated for the mri of the brain and spine where it improves the detection of lesions and provides diagnostic information additional to that obtained with unenhanced mri. multihance is indicated for contrast enhance magnetic resonance angiography to improve the diagnostic accuracy of detecting clinical significant steno-occlusive vascular diseases in patients with known vascular diseases of the abdominal, supra-aortic or peripheral arteries.

Canada - English - Health Canada

jubilant draximage inc. dba jubilant radiopharma - gadopentetate dimeglumine - solution - 469mg - gadopentetate dimeglumine 469mg - other diagnostic agents

Canada - English - Health Canada

avir pharma inc. - gadopentetate dimeglumine - solution - 469mg - gadopentetate dimeglumine 469mg - miscellaneous therapeutic agents

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - gadobutrol (unii: 1bj477io2l) (gadolinium cation (3+) - unii:azv954tz9n) - gadobutrol injection is indicated for use with magnetic resonance imaging (mri) in adult and pediatric patients, including term neonates to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system. gadobutrol injection is indicated for use with mri in adult patients to assess the presence and extent of malignant breast disease. gadobutrol injection is indicated for use in magnetic resonance angiography (mra) in adult and pediatric patients, including term neonates, to evaluate known or suspected supra-aortic or renal artery disease. gadobutrol injection is indicated for use in cardiac mri (cmri) to assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (cad). gadobutrol injection is contraindicated in patients with history of severe hypersensitivity reactions to gadobutrol injection. gbcas cross the placenta and result in fetal exposure and gadolinium retention.

United States - English - NLM (National Library of Medicine)

slate run pharmaceuticals, llc - gadobutrol (unii: 1bj477io2l) (gadolinium cation (3+) - unii:azv954tz9n) - gadobutrol injection is indicated for use with magnetic resonance imaging (mri) in adult and pediatric patients, including term neonates to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system. gadobutrol injection is indicated for use with mri in adult patients to assess the presence and extent of malignant breast disease. gadobutrol injection is indicated for use in magnetic resonance angiography (mra) in adult and pediatric patients, including term neonates, to evaluate known or suspected supra-aortic or renal artery disease. gadobutrol injection is indicated for use in cardiac mri (cmri) to assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (cad). gadobutrol injection is contraindicated in patients with history of severe hypersensitivity reactions to gadobutrol injection. gbcas cross the placenta and result in fetal exposure and gadolinium retention.

Canada - English - Health Canada

bracco imaging canada - gadobenate dimeglumine - solution - 529mg - gadobenate dimeglumine 529mg - other diagnostic agents